Michl M, Fabianska M, Seeböck P, et al. - Utilizing artificial intelligence-based fluid quantification, researchers sought to objectively evaluate disease activity and treatment response in patients with retinal vein occlusion, neovascular age-related macular degeneration and centre-involved diabetic macular oedema. The sample consisted of 2,311 patients from five clinical, multicentre trials, who received a flexible antivascular endothelial growth factor (anti-VEGF) therapy over a 12-month period. Fully automated intraretinal fluid (IRF)/subretinal fluid (SRF) localisation and quantification over time shed light on the fluid dynamics in each disease. In all diseases studied, there is a specific anatomical response of IRF/SRF to anti-VEGF therapy.